For licensed healthcare professionals. The protocol figures below are drawn from published labeling and peer-reviewed literature for educational reference. They are not a prescription, not a recommendation, and not a substitute for the dispensing pharmacy's labeling or your own clinical judgment.
Metabolic
Adipotide
aka FTPP
Not WADA-listed
Pro-apoptotic targeted peptide that disrupts adipose vasculature. Preclinical only; nephrotoxicity observed at high doses.
At a glance
- Common vial size
- 5 mg
- Reference dose
- 1 mg
- Frequency
- Cycled — provider supervised
Clinical notes
- Renal toxicity signal in primate studies — not routine use
Available formulations
Presentations carried across the VitaRelay pharmacy network, including 503A compounded, 503B outsourcing facility, and research & development sourcing. Pricing and state-level availability are shown to verified accounts only.
- 0 · Lyophilized PowderRUO
- Lyophilized PowderRUO
References
Often used with
Compounds commonly discussed alongside Adipotide in published protocols and prescriber requests. Listed for reference only — not a clinical recommendation, and not a suggestion to co-administer.
Pricing and ordering are for verified accounts
VitaRelay serves licensed practices, prescribers, and pharmacies. Catalog pricing, availability by state, and ordering are available after your account is verified.
Also in Metabolic
5-Amino-1MQ
Small-molecule NNMT inhibitor under study for adipose-tissue methyl donor preservation, fat loss, and sarcopenia. Oral capsule.
AOD-9604
C-terminal fragment of human GH studied for lipolysis without affecting glucose or IGF-1. Did not meet endpoints in obesity trials.
AICAR
AMPK activator studied for exercise mimetic and metabolic effects. WADA-prohibited as a metabolic modulator.
MOTS-c
Mitochondrial-derived peptide implicated in metabolic homeostasis and insulin sensitivity. Preclinical/early human research only.
Tesofensine
Triple monoamine reuptake inhibitor in Phase III for obesity (TIPO-4). Oral, once daily.